Severe cutaneous adverse reactions to drugs

Чтобы посмотреть этот PDF файл с форматированием и разметкой, скачайте файл и откройте на своем компьютере.
Published online May 2, 2017 Severe cutaneous adverse reactions to drugs Tu Anh Duong, Laurence Valeyrie-Allanore, Pierre Wolkenstein, Olivier Chosidow During the past decade, major advances have been made in the accurate diagnosis of severe cutaneous adverse reactions Classication and diagnosis and greyish-white pseudo membranes coat oral-cavity haemorrhagic erosions, with crusts being the main lesions (appendix p 13). Conjunctival lesions, including hyperaemia, erosions, chemosis, photophobia, and tearing comprise eye involvement. Severe forms lead to corneal ulceration, anterior uveitis, or purulent conjunctivitis Visceral involvement associated with Stevens-Johnson syndrome and toxic epidermal necrolysis consists of transient liver or renal enzyme increases or bronchial and Although rare, specic acute visceral failures in Stevens-Johnson syndrome and toxic epidermal necrolysis should be suspected and documented after eliminating bacterial or viral super infection. No specic score or diagnostic test is available for the diagnosis of Stevens-Johnson syndrome and toxic epidermal necrolysis. The diagnosis mainly relies on identication of a broad range of clinical signs and ). Full-thickness and a negative direct are mandatory for diagnosis. forme major, linear IgA bullous dermatosis (appendix p 15; spontaneous or drug-related), generalised xed drug eruption (appendix p 16), supercial burns, cytotoxic drug It usually begins 2–6 weeks after drug exposure. The diculty in diagnosing DRESS and SCAR involved Severity Score system for SJS and TEN days Fever 38°C, inuenza-like syndrome, respiratory tract Published online May 2, 2017 including fever, lymphadenopathy, inuenza-like symptoms, burning pain, or pruritus, can precede the Clinical dermatological symptoms consist of facial oedema, erythroderma, distal To reduce misdiagnosis, several invest (table 2), such as those to identify blood abnormalities indicating visceral involvement, virus reactivation, hypereosinophilia, atypical lymphocytes, and hypogammaglobulinaemia during the acute stage. As rst hypothesised in 1994, reactivation of a single or multiple human herpesvirus (HHV) family members, with HHV6 being the most described. This HHV6 viral Suggested conrmation tests Tests Erythema multiforme major, Mycoplasma pneumoniae infection*, coxsackievirus infection, linear IgA bullous dermatosis, generalised bullous xed-drug eruption, Several mechanistic models have been proposed to explain the recognition by T cells of small compounds allopurinol-induced Stevens-Johnson syn drome and toxic These associations were rst identied in countries with a high Published online May 2, 2017 In allopurinol-induced SCARs, studies have identied Figure : Immune mechanisms of SCARs Schematic diagram showing the immune stimulation, cytotoxic T-cell activation, and key actors in the development of SCARs, adapted from Pichler and colleagues. (covalent) Cytotoxic T-cell Cytotoxic protein Drug-specic T cells T-cell hypothesis Peptide A Drug or Peptide A Peptide B T cells CD8+ T cells T- reg SJS and TEN CD8+ cytoxic T cells CD1+ and CD14+ CD14+ and CD16+ Fas–Fas ligand Perforin–granzyme B Identication of specic CD8+ cytoxic T cells CXCL8 CD8+ cytoxic T cells Identication of specic specic immune activation such as occurs in a viral T-reg functions during acute and chronic SCAR stages By comparison with healthy controls, T-reg frequency in early and late stages of Stevens-Johnson syndrome and toxic epidermal necrolysis did not dier, whereas non-T-reg cell frequency was increased upon resolution of Stevens-Johnson syndrome and toxic epidermal In the acute stage of DRESS syndrome, functional T-regs were dramatically expanded, whereas they were profoundly diminished in Stevens-Johnson By contrast, T-regs became functionally decient upon resolution of DRESS syndrome, whereas their functionality was restored after Stevens-Johnson syndrome and toxic Assessment of SCARs Case assessment relies on the eruption’s clinical associated symptoms (eg, fever, pruritus, lymphadenopathy), and the Published online May 2, 2017 Physical examination includes the description of the distribution of SCAR-specic lesions. Cutaneous or mucous membrane involvement in orices, indicating a severe reaction (external or internal), must be specied. Photos and clinical signs should be collected as often as Treatment stage SJS and Drug withdrawal, no RCT-validated curative treatment* Supportive care strongly feeding, uid-loss treatment, involvement, lung Dystrophic scars, hyperpigmentation, alopecia, nail loss, visual loss, synechiae, dry eye, symblepharon, dental agenesia, sialadenitis, tooth decay, genital synechiae, psychiatric disorders Patch testing at month 6; follow-up† at least at month 2, month 6, month 12, and every year for 5 years; specialist consultations: dermatology, ophthalmology, ear, nose, and throat examination, gynaecology, psychiatry, Drug withdrawal, no RCT-validated curative treatment‡; topical or according to disease severity amides) are not recommended. When necessary, non-adhesive (eg, hydrocellular) dressings are used to cover pressure points, particularly on the During the acute phase, ocular, oral, nasal, genital, or anal mucosa lubrications with emollient are recommended to reduce mucosal adhesion formation and functional Mucosal bleeding or erosions are treated with topical analgesia, mouthwashes, application of swabs, Ocular management relies on inammatory debris removal with daily saline rinses, and, after topical anaesthesia, removal with a moist cotton bud or smooth blunt instrument. Prophylactic topical antibiotics, topical ciclosporin, or corticosteroids have been used, but were To protect and reduce conjunctival or corneal sequelae, amniotic membrane transplantation has been proposed to For DRESS syndrome and AGEP, dermatological care mainly relies on appropriate skin moisturisation. When necessary, mucous-membrane management should be the same as that used for Stevens-Johnson syndrome and anti-TNF &#x/MCI; 12;� 0;&#x/MCI; 12;� 0;89,90&#x/MCI; 12; 0;&#x/MCI; 12; 0; or steroids with or without IVIg, complication or mortality rates did not signicantly dier with the addition of IVIg, whereas hospital stays were signicantly shorter for those receiving Furthermore, mortality did not signicantly dier in patients receiving IVIg or corticosteroids in comparison Drug withdrawal Facial oedema Facial oedema Fixed drug eruption Published online May 2, 2017 progression after a short-term administration of This potential benet of ciclosporin on mortality of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, compared with IVIg, was also In an uncontrolled series of ten patients with toxic SCARs—mainly Stevens-Johnson syndrome, toxic epi dermal necrolysis, and DRESS syndrome—are life threatening and carry a non-negligible risk of severe Johnson syndrome and toxic epidermal necrolysis, visceral involvement (eg, renal failure, intestinal, ocular- specic pulmonary lesions, or sepsis) is the main Respiratory insuciency in patients with SCARs can result from direct eects of the SCAR on the organs or inhalation of foreign substances leading to superinfection, and pulmonary infection is signicantly associated with severe laryngeal lesions caused by Stevens-Johnson syndrome or toxic epi During the acute stage, impaired skin barrier function or translocation of gut bacteria might facilitate bacterial Sepsis is the Johnson syndrome and toxic epidermal necrolysis. In a Johnson syndrome or toxic epidermal necrolysis, therapy SCORTEN successfully predicts 3-day mortality Johnson syndrome and toxic epidermal necrolysis when A ve-point auxiliary score that does not require laboratory data has also been devised, and might be useful to predict severity of illness In a cohort study, the overall cumulative incidence of long-term DRESS sequelae was 11·5%, and If PTSD, Published online May 2, 2017 HIV association might be aected by the severity of the patient’s immunodeciency or the use of drugs that are (eg, co-trimoxazole or abacavir) in this even though for nevirapine, hypersensitivity predominated in non-HIV-infected patients with high prophylactic treatment after HIV exposure. For abacavir, in-vitro T-cell reactivity can also occur in drug-naive individuals with the HLA-B*57:01 allele. Supported by the results of extensive HLA-B*15:02 screening in Taiwanese neurology clinics, the US Food and Drug Administration recommends for AGEP than for Stevens-Johnson syndrome, toxic Patch tests are reportedly safe, with few reported relapses or severe reactions. Neither prick nor intradermal tests are higher sensitivity than the prick test, and an oral drug tests are done 6 months after the acute stage to avoid In-vitro tests can be used to measure peripheral blood mononuclear cell activity in patients with SCARs, with the culprit drug displaying pharmacological activity. For Neither are done routinely. Although LLT shows promise as a culprit-drug test in patients with DRESS syndrome or AGEP, it has low relevance in Stevens-Johnson syndrome and toxic epidermal necrolysis, even after enhancement of its sensitivity after removal of T-reg CD25+ cells. ELISPOT Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med Kardaun SH, Sekula P, V multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Bastuji-Garin S, F ouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic J Am Acad Dermatol and drug hypersensitivity syndrome (Drug Rash with Eosinophilia Semin Cutan Med Surg 250–57. Descamps V, V herpesvirus 6 infection with drug reaction with eosinophilia and Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses same sequential order as in graft-versus-host disease. Kardaun SH, Sidoro A, V Variability in the Shiohara T, I ijima M, Ikezawa Z, Hashimoto K. The diagnosis of a Ortonne N, Valeyrie-Allanore L, Bastuji-G Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Sidoro A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)—a clinical J Cutan Pathol Kardaun SH, Kuiper H, F idler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous J Cutan Pathol Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1600–07. management and outcomes; recording of patients’ viewpoints and encouraging the use of patient , which have contributed to improving patients’, health-care providers’, and decision makers’ knowledge of outcomes and sequelae associated with Stevens-Johnson syndrome and toxic epidermal necrolysis; and establishment of specic funds to nancially compensate patients with SCARs and improvement of patients’ awareness of these funds. For a potentially high-risk drug, several decisions Published online May 2, 2017 for assessment of drug causality in Stevens-Johnson Syndrome and Stevens-Johnson syndrome after Pediatr Transplant E74–77. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. 302–07. Gueudry J, Roujeau J-C, Binaghi M, Soubrane G, Muraine M. Stevens-Johnson syndrome and toxic epidermal necrolysis. Lebargy F, Wolkenstein P, G Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med Cho YT, Lin JW Generalized bullous xed drug eruption is distinct from Stevens-Johnson syndrome/toxic J Am Acad Dermatol coxsackievirus a6 new variant induced widespread mucocutaneous Klimas NK, Dominguez AR, Vandergri TW . Bullae and atypical Shiohara T, Inaoka M, Kano Y Twelve-year analysis of severe Ishida T, Kano Y , Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: generalized exanthematous pustulosis (AGEP)-results of a of 36 Korean patients with acute generalized exanthematous involvement in acute generalized exanthematous pustulosis: Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular Toxic epidermal 360–67. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug Padovan E, Mauri-Hellweg D, Pichler WJ, Weltzien HU. Wei C-Y, Chung W-H, Huang H-W, Chen Y-T, Hung S-I. Illing PT, V Immune self-reactivity triggered by drug-modied HLA-peptide repertoire. Ostrov DA, Grant BJ, P caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA Cheng C-Y, S u S-C, Chen C-H, Chen W-L, Deng S-T, Chung W-H. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. Chung W-H, H A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related hypersensitivity to abacavir. N Engl J Med Kaniwa N, Saito Y HLA–B*15:11 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. 2010; Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal N Engl J Med leukocyte antigen alleles and Nevirapine hypersensitivity in a malawian HIV-infected population. Rare variations in IL36RN in severe adverse drug reactions 1904–07. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson Chung WH, Pan RY possess preferential TCR clonotypes and express granulysin in Stevens-Johnson syndrome and toxic epidermal necrolysis across agent inhibits cytotoxic T lymphocyte-mediated immune disorders. Possible involvement Stevens-Johnson syndrome and toxic epidermal necrolysis. Chung W-H, H for disseminated keratinocyte death in Stevens-Johnson syndrome Nat Med potential inducers of Fas-mediated keratinocyte apoptosis through associated with severity and mortality in Stevens-Johnson Kim SK, Kim W-J, Y potentiates MLKL phosphorylation-mediated programmed 2015; Hashizume H, Fujiyama T, Kanebayashi J, Kito Y, Hata M, Yagi H. herpesvirus-6 reactivation in drug allergy. Sci Transl Med Hapten-specic TH17 cells Rapid immunochromatographic Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol Evaluation of serum cytokine levels in toxic epidermal necrolysis and Stevens-Johnson three subpopulations of CD4(+)Foxp3(+) regulatory T cells in Stevens-Johnson syndrome and toxic epidermal necrolysis patients. Increased ratio of FoxP3+ Hanafusa T, Azukizawa H, Matsumura S, Katayama I. The predominant drug-specic T-cell population may switch from anticonvulsant-induced hypersensitivity. N Engl J Med Haute Autorité de la Santé. Necrolyse epidermique toxique syndrome Kaenberger BH, Rosenbach M. T J Am Acad Dermatol ciclosporin treatment for Stevens-Johnson syndrome and toxic Struck MF, Hilbert P, M ockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn Intensive Care Med management of Stevens-Johnson syndrome/toxic epidermal 1194–227. Toxic epidermal necrolysis and Stevens-Johnson syndrome: 323–27. Toxic epidermal experience with Stevens-Johnson syndrome and toxic epidermal Burns de Prost N, Mekontso-Dessap A, V Acute respiratory failure in patients with toxic epidermal necrolysis: Crit Care Med Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal J Am Acad Dermatol Lin A, Patel N, Y oo D, DeMartelaere S, Bouchard C. Management of Stevens-Johnson syndrome/toxic epidermal necrolysis. J Burn Care Res Liu J, Sheha H, Fu Y , Giegengack M, Tseng SCG. Oral mucosal graft with amniotic membrane transplantation for total limbal stem cell deciency. 739–47.e1. Schneck J, Fagot J-P, S ekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Eects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and Lee HY, Dunant A, S use on the clinical course of Stevens-Johnson syndrome and toxic from the multinational EuroSCAR and RegiSCAR studies. Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Bachot N, Revuz J, R treatment for Stevens-Johnson syndrome and toxic epidermal Chen J, Wang B, Z eng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome Huang YC, Li YC, Chen TJ. The ecacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: Lee HY, Lim YL, Thirumoorthy T , Pang SM. The role of intravenous Kirchhof MG, Miliszewski MA, S ikora S, Papp A, Dutz JP. de Sica-Chapman A, Williams G, Soni N, Bunker CB. Granulocyte Chelsea & Westminster TEN management protocol. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and Ten cases of drug 2012; Published online May 2, 2017 Ingen-Housz-Oro S, H Acute generalized de Prost N, Ingen-Housz-Oro S, Duong T Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) Knight L, Todd G, M uloiwa R, Matjila M, Lehloenya RJ. Stevens Johnson syndrome and toxic epidermal necrolysis: Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau J-C, Revuz J. Performance of the SCORTEN during the rst ve days of Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res Duong TA, de Prost N, Ingen-H Stevens-Johnson function after remission. Severe and unrecognized dental abnormalities after drug-induced epidermal Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal Acta Derm Venereol Sant’ Anna AE, Hazarbassanov RM, de Freitas D, Gomes JÁP. Minor salivary glands and labial mucous membrane graft in the Stevens-Johnson syndrome. function after scleral lens tting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Struck MF, Illert T, Liss Y , Bosbach ID, Reichelt B, Steen M. Toxic epidermal necrolysis in pregnancy: case report and review of J Burn Care Res Chen YC, Chang CY, Cho YT , Chiu HC, Chu CY. Long-term sequelae of Lew TT, Creamer D, Mackenzie J, Walsh SA. Post-traumatic stress 836–37. Association of human herpesvirus 6 reactivation with the aring and severity of drug-induced Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and Med Clin North Am Ushigome Y, Kano Y , Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity J Am Acad Dermatol Bégaud B, Evreux JC, J 1981; : 239–45. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Levi N, Bastuji-Garin S, M Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis Pediatrics associated with drugs and vaccines in children: a case-control study. Telaprevir-related Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Stevens-Johnson syndrome/toxic epidermal necrolysis related to 2017; published online Jan 17. DOI:10.1016/j.jid.2016.11.041. Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry Abacavir induced T cell Carbamazepine-induced toxic eects and HLA–B*15:02 screening in Taiwan. N Engl J Med Taiwan. JAMA Intern Med 1550–57. Recurrence of drug-induced reactions in DRESS patients. J Eur Acad Dermatol Venereol Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse Stern RS. Recurrence of Stevens-J Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. drug sensitivity: dependence on its timing and the type of drug Srinoulprasert Y, P eective during the acute phase of delayed-type drug Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome—alternatives for lymphocyte 1027–37. Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly Severe cutaneous adverse reactions to drugs: from patients to the national Lebrun-Vignes B, Kref t-Jais C, Castot A, Chosidow O. Comparative Nanry KP. The eect of dermatologic precautions on the incidence disorder: a randomized trial. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis.

Приложенные файлы

  • pdf 14832517
    Размер файла: 878 kB Загрузок: 0

Добавить комментарий